Cytokinetics, Inc. (CYTK) stock saw a modest uptick, ending the day at $50.75 which represents a slight increase of $2.89 or 6.04% from the prior close of $47.86. The stock opened at $47.75 and ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

The Metrolinx award includes an initial firm order for 80 45-foot D45 CRT diesel commuter coaches along with a number of options that were added to NFI's fourth quarter 2024 backlog. The contract also ...